Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab after venetoclax-obinutuzumab for measurable residual disease-directed treatment in chronic lymphocytic leukemia
ACTRN12625000387426Phase 2Recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Dec 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of epcoritamab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 cohorts), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoints: Cohort 1 proportion achieving U-MRD4 after 6 months of epcoritamab and Cohort 2 proportion converting to MRD4 positivity by 2 years. Started Dec 2025; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12625000387426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000387426.